Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...

Corporates don't want Copilot Software King of the World, Microsoft is finding out the hard way that even a decades-long grip ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

The AMG Montrusco Bolton Large Cap Growth Fund returned -5.88% during the first quarter, compared to the -8.47% return for ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

Keurig Dr Pepper Inc. (NASDAQ:KDP) is one of the 12 stocks on Jim Cramer’s radar recently. A caller asked if the company ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...